Note
Background: The Ebolavirus (EBOV) is extremely lethal with mortalityrates ranging from twenty-three to ninety percent. No licensed Ebola vaccine exists and classical protocols for vaccine design do not comply. One solution, rational vaccine design (RVD) is based on two parameters: (1.) identification of epitopes, antigenic peptides that mediatethe cellular immune system and (2.) exploitation of the immune system’s ability to recognize and remember vaccines.